INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 March 2017
Net Assets |
£242m |
Net Assets per share |
645p |
Share price |
596p |
Total value of unquoted investments |
£24m |
Total number of portfolio companies |
87 |
Top Ten Holdings
Company Name |
% NAV |
Celgene |
7.2 |
Biogen |
6.8 |
Regeneron |
5.8 |
Incyte |
5.6 |
Alexion |
5.0 |
Genmab |
4.9 |
Vertex |
4.4 |
Shire |
3.9 |
Amgen |
3.6 |
Illumina |
3.3 |
|
----------- |
Total |
50.5 |
Geographical Allocation |
% NAV |
US & Canada |
83 |
Europe & UK |
17 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
90 |
Unquoted |
10 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
55 |
Mid Cap =USD1-10BN |
23 |
Small Cap <USD1BN |
22 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
38 |
Orphan |
12 |
CNS |
12 |
Inflammation |
8 |
Ophthalmology |
8 |
Medtech |
2 |
Other |
20 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
19 APRIL 2017